文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024.

作者信息

Thill Marc, Janni Wolfgang, Albert Ute-Susann, Banys-Paluchowski Maggie, Bauerfeind Ingo, Blohmer Jens, Budach Wilfried, Dall Peter, Ditsch Nina, Fallenberg Eva Maria, Fasching Peter A, Fehm Tanja, Friedrich Michael, Gerber Bernd, Gluz Oleg, Harbeck Nadia, Hartkopf Andreas, Heil Jörg, Huober Jens, Jackisch Christian, Kolberg-Liedtke Cornelia, Kreipe Hans-Heinrich, Krug David, Kühn Thorsten, Kümmel Sherko, Loibl Sibylle, Lüftner Diana, Lux Michael Patrick, Maass Nicolai, Mundhenke Christoph, Reimer Toralf, Rhiem Kerstin, Rody Achim, Schmidt Marcus, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Solbach Christine, Solomayer Erich-Franz, Stickeler Elmar, Thomssen Christoph, Untch Michael, Witzel Isabell, Wöckel Achim, Würstlein Rachel, Müller Volkmar, Park-Simon Tjoung-Won

机构信息

Klinik für Gynäkologie und Gynäkologische Onkologie, Agaplesion Markus Krankenhaus, Frankfurt, Germany.

Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany.

出版信息

Breast Care (Basel). 2024 Jun;19(3):183-191. doi: 10.1159/000538753. Epub 2024 Apr 10.

DOI:10.1159/000538753
PMID:38894953
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11182633/
Abstract

The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2024 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer.

摘要

相似文献

[1]
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024.

Breast Care (Basel). 2024-6

[2]
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022.

Breast Care (Basel). 2022-8

[3]
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025.

Breast Care (Basel). 2025-3-8

[4]
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023.

Breast Care (Basel). 2023-8

[5]
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.

Breast Care (Basel). 2024-6

[6]
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023.

Breast Care (Basel). 2023-8

[7]
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019.

Breast Care (Basel). 2019-8

[8]
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025.

Breast Care (Basel). 2025-3-8

[9]
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.

Breast Care (Basel). 2022-8

[10]
ABC7 Consensus: Assessment by a German Group of Experts.

Breast Care (Basel). 2024-4

引用本文的文献

[1]
Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast Cancer.

Geburtshilfe Frauenheilkd. 2025-5-15

[2]
Prognostic Factors in Therapy Regimes of Breast Cancer Patients with Brain Metastases: A Retrospective Monocentric Analysis.

Cancers (Basel). 2025-1-15

本文引用的文献

[1]
Intrathecal Therapy Options for Meningeal Carcinomatosis.

Geburtshilfe Frauenheilkd. 2023-11-8

[2]
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023.

Breast Care (Basel). 2023-8

[3]
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.

Lancet. 2023-10-21

[4]
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

Ann Oncol. 2023-9

[5]
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.

N Engl J Med. 2023-6-1

[6]
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.

J Clin Oncol. 2023-8-20

[7]
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.

Lancet. 2023-1-14

[8]
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.

JAMA Oncol. 2023-2-1

[9]
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

J Clin Oncol. 2022-10-1

[10]
Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions.

Eur J Cancer. 2022-5

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索